Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AVACTA GROUP PLC

Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
From AVACTA GROUP PLC
Via GlobeNewswire
Avacta Appoints Brian Hahn as Chief Financial Officer
From AVACTA GROUP PLC
Via GlobeNewswire
Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
From Avacta Group plc
Via Business Wire
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
From Avacta Group plc
Via Business Wire
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
From Avacta Group plc
Via Business Wire
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
From Avacta Group plc
Via Business Wire
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
From Avacta Group plc
Via Business Wire
Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting
From Avacta Group plc
Via Business Wire
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
From Avacta Group plc
Via Business Wire
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration
From Avacta Group plc
Via Business Wire
Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort
From Avacta Group plc
Via Business Wire
LG Chem Renews License Triggering Payment to Avacta
From Avacta Group plc
Via Business Wire
AffyXell Expands its Strategic Partnership With GenScript ProBio
From Avacta Group plc
Via Business Wire
Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake
From Avacta Group plc
Via Business Wire
Avacta Appoints Dr Christina Coughlin as Non-Executive Director
From Avacta Group plc
Via Business Wire
Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin
From Avacta Group plc
Via Business Wire
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
From Avacta Group plc
Via Business Wire
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
From Avacta Group plc
Via Business Wire
Avacta Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant
From Avacta Group plc
Via Business Wire
Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
From Avacta Group plc
Via Business Wire
Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership
From Avacta Group plc
Via Business Wire
Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial
From Avacta Group plc
Via Business Wire
Avacta’s Diagnostic Division Achieves ISO 13485 Certification
From Avacta Group plc
Via Business Wire
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant
From Avacta Group plc
Via Business Wire
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Distribution Agreement
From Avacta Group plc
Via Business Wire
Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU
From Avacta Group plc
Via Business Wire
MHRA Confirms Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test
From Avacta Group plc
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.